Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Hospices Civils de Lyon
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02690857CT.gov Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cystic Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sunflower Oil (this asset) | Hospices Civils de Lyon | P2 | CCC · 50 |
| Tezacaftor | Vertex Pharmaceuticals Incorporated | P4 | A |
| Ivacaftor | Meyer Children's Hospital IRCCS | P4 | A |
| Lumacaftor | Hospices Civils de Lyon | P4 | BBB |
| Liprotamase | Anthera Pharmaceuticals | P4 | BBB |
| Elexacaftor | Meyer Children's Hospital IRCCS | P4 | BBB |
| vx-121 | Vertex Pharmaceuticals Incorporated | P3 | BBB |
| Azithromycin | Hospices Civils de Lyon | P4 | BBB |
| Colistin | Liverpool Heart and Chest Hospital NHS Foundation Trust | P4 | BBB |
+42 more in the Cystic Fibrosis cohort
Other indications for Sunflower Oil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cognitive Disorder | — | N/A | D · 30 |
| Obesity Disorder | — | N/A | D · 26 |
| Panniculitis | — | N/A | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sunflower Oil in Cystic Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sunflower-oil-cystic-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →